Trial Profile
A Randomized, Controlled, Multi-center, Phase III Clinical Study to Investigate Recombinant Humanized PD-1 Monoclonal Antibody Injection (JS001) Versus Dacarbazine as the 1st-line Therapy for Unresectable or Metastatic Melanoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 22 Aug 2023
Price :
$35
*
At a glance
- Drugs Toripalimab (Primary) ; Dacarbazine
- Indications Malignant melanoma
- Focus Registrational; Therapeutic Use
- Sponsors Shanghai Junshi Biosciences
- 15 Aug 2023 Planned End Date changed from 1 Dec 2021 to 30 Jun 2024.
- 15 Aug 2023 Planned primary completion date changed from 1 Jun 2021 to 31 Dec 2023.
- 15 Aug 2023 Status changed from recruiting to active, no longer recruiting.